Aniwan Satimai, Viriyautsahakul Vichai, Luangsukrerk Thanawat, Angsuwatcharakon Phonthep, Piyachaturawat Panida, Kongkam Pradermchai, Kongtab Natanong, Treeprasertsuk Sombat, Kullavanijaya Pinit, Rerknimitr Rungsun
Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, 10330, Thailand.
Division of General Internal Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Surg Endosc. 2021 May;35(5):2119-2125. doi: 10.1007/s00464-020-07615-3. Epub 2020 May 7.
Double-balloon endoscopy (DBE) provides both diagnosis and treatment in overt obscure gastrointestinal bleeding (OGIB). The aim of this study was to evaluate the rebleeding rate after DBE.
This retrospective review was conducted between January 2006 and July 2018, 166 patients with overt OGIB who underwent DBE were enrolled. Therapeutic intervention was defined as endoscopic treatment, embolization, or surgery. Primary outcome was rebleeding rate after DBE. The patients were divided into 3 groups based on their DBE; (1) positive DBE requiring therapeutic intervention (G1), (2) positive DBE without therapeutic intervention required (G2) and (3) negative DBE (G3). Cumulative incidence of rebleeding was estimated using the Kaplan-Meier method. Cox regression was used to assess the association of DBE with rebleeding risk. This study was approved by our Institutional Review Board.
Sixty-eight patients (41%) were categorized in G1, 34 patients (20%) in G2 and 64 patients (39%) in G3. Overall rebleeding occurred in 24 patients (15%). The cumulative incidence of rebleeding for G1 was the lowest. The 1-year and 2-year cumulative probability of developing rebleeding after DBE in G1 were 3.5% and 3.5%, 8.2% and 14.0% in G2, and 18.2% and 20.6% in G3, respectively (p = 0.02). After adjusting for bleeding severity and comorbidities, patients with positive DBE requiring therapeutic intervention had a significantly lower rate of rebleeding when compared with patients who did not receive intervention (hazard ratio 0.17; 95% CI 0.03-0.90).
DBE-guided therapeutic intervention was associated with a lower risk of rebleeding when compared with those with negative and positive DBE without therapeutic intervention. One-fifth of patients with overt OGIB had false negative after DBE.
双气囊小肠镜检查(DBE)可用于显性不明原因胃肠道出血(OGIB)的诊断和治疗。本研究旨在评估DBE后的再出血率。
本回顾性研究在2006年1月至2018年7月期间进行,纳入了166例接受DBE的显性OGIB患者。治疗性干预定义为内镜治疗、栓塞或手术。主要结局是DBE后的再出血率。根据DBE情况将患者分为3组:(1)需要治疗性干预的阳性DBE(G1),(2)无需治疗性干预的阳性DBE(G2)和(3)阴性DBE(G3)。采用Kaplan-Meier法估计再出血的累积发生率。使用Cox回归评估DBE与再出血风险的关联。本研究经我院机构审查委员会批准。
68例患者(41%)归入G1组,34例患者(20%)归入G2组,64例患者(39%)归入G3组。24例患者(15%)发生了总体再出血。G1组的再出血累积发生率最低。G1组DBE后1年和2年发生再出血的累积概率分别为3.5%和3.5%,G2组为8.2%和14.0%,G3组为18.2%和20.6%(p = 0.02)。在调整出血严重程度和合并症后,需要治疗性干预的阳性DBE患者与未接受干预的患者相比,再出血率显著更低(风险比0.17;95%可信区间0.03 - 0.90)。
与阴性DBE和无需治疗性干预的阳性DBE相比,DBE引导的治疗性干预与再出血风险较低相关。五分之一的显性OGIB患者在DBE后出现假阴性。